

CLAIMS

1. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof comprises
a light chain variable region comprising a CDR1 selected from SEQ ID No.: 1, a CDR2 selected from SEQ ID No.: 2, and a CDR3 selected from SEQ ID No.: 53; and
a heavy chain variable region comprising a CDR1 selected from SEQ ID No.: 4, a CDR2 selected from SEQ ID No.: 5, and a CDR3 selected from SEQ ID No.: 6 wherein X is selected from A, Q or N.
2. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof comprises
a light chain variable region comprising SEQ ID No.: 11, and
a heavy chain variable region comprising SEQ ID No.: 16, wherein X is selected from A, Q or N.
3. A Tau-binding antibody or binding fragment thereof of claim 2, wherein the heavy chain variable region comprises SEQ ID No.: 14 or 15.
4. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof competes for binding to Tau with a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, or 3.
5. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof binds to the same epitope of Tau as a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, or 3.
6. A Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, or 5, wherein said Tau-binding antibody or binding fragment thereof is a monoclonal humanized antibody.

7. A Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, or 6, wherein said Tau-binding antibody or binding fragment thereof binds to a phosphorylated Tau region within the amino acids 197 to 206 of SEQ ID No.: 55.
8. A Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, or 7, wherein said Tau-binding antibody or binding fragment thereof binds to soluble forms of human Tau , paired helical filaments (PHF) of human Tau or to both soluble forms of human Tau and paired helical filaments (PHF) of human Tau .
9. An isolated nucleic acid molecule encoding the light and/or heavy chain of a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, or 8.
10. A cloning or expression vector comprising one or more nucleic acid sequences of claim 9.
11. A host cell comprising one or more nucleic acid sequences of claim 9 or one or more cloning or expression vectors of claim 10.
12. A method of producing a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, or 8 comprising at least the steps of
 - c) culturing a host cell of claim 11, and
 - d) isolating said Tau-binding antibody or binding fragment thereof.
13. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, or 8 for use as a therapeutically active agent.
14. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, or 8 for use in treating a tauopathy.
15. An isolated Tau-binding antibody or binding fragment thereof for use of claim 14, wherein said tauopathy is Alzheimer's disease or progressive supranuclear palsy.
16. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, or 8 for use as a diagnostic agent.

17. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, or 8 for use in diagnosing a tauopathy.
18. An isolated Tau-binding antibody or binding fragment thereof for use of claim 17, wherein said tauopathy is Alzheimer's disease or progressive supranuclear palsy.
19. Use of an isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, or 8 in the manufacture of a medicament for the treatment of tauopathy.
20. The use according to claim 19, wherein said tauopathy is Alzheimer's disease or progressive supranuclear palsy.